+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antithrombotic Drugs Market by Drug Class, Indication, Route Of Administration, End User - Global Forecast to 2030- Product Image
Antithrombotic Drugs Market by Drug Class, Indication, Route Of Administration, End User - Global Forecast to 2030- Product Image
Sale

Antithrombotic Drugs Market by Drug Class, Indication, Route Of Administration, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6013888
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The antithrombotic drugs market is experiencing profound transformation as advancements in clinical practice and industry strategy redefine the standard of care in cardiovascular treatment. Senior leaders face new imperatives to align portfolios, operations, and partnerships with the evolving dynamics of this complex healthcare segment.

Market Snapshot: Antithrombotic Drugs Market Outlook

The antithrombotic drugs market grew from USD 42.47 billion in 2024 to USD 45.15 billion in 2025 and is projected to reach USD 60.49 billion by 2030, reflecting a CAGR of 6.06%. As cardiovascular disease prevalence persists across developed and emerging economies, pharmaceutical and healthcare players are adapting to changing therapeutic approaches, regulatory requirements, and patient needs. Decision-makers can anticipate ongoing shifts in therapy adoption and regional performance as innovative products and digital health solutions converge with new pricing and supply chain realities.

Scope & Segmentation

  • Drug Class: Anticoagulants, Direct Oral Anticoagulants, Direct Thrombin Inhibitors (Dabigatran), Factor Xa Inhibitors (Apixaban, Edoxaban, Rivaroxaban), Heparins (Low Molecular Weight, Unfractionated), Vitamin K Antagonists, Antiplatelets, Thrombolytics.
  • Indication: Atrial Fibrillation, Deep Vein Thrombosis, Myocardial Infarction, Pulmonary Embolism, Stroke Prevention.
  • Route of Administration: Oral (Tablet), Parenteral (Injection).
  • End User: Home Care, Hospital, Retail Pharmacy.
  • Regions: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Companies: Bayer Aktiengesellschaft, Pfizer Inc., Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Johnson & Johnson, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, Novartis AG, Merck & Co., Inc.

Key Takeaways for Senior Decision-Makers

  • Direct oral anticoagulants represent the leading edge of clinical adoption, changing patient management strategies and enabling simplified administration in diverse care settings.
  • Tailored treatment protocols emphasize patient-specific risk assessment, precision medicine, and collaborative decision-making between clinicians and payers.
  • The growing adoption of digital health platforms supports real-time therapeutic monitoring, improving clinician responsiveness and patient adherence.
  • Strategic manufacturing alliances and near-shoring initiatives are vital for supporting market access amid evolving regulatory frameworks.
  • Market entry strategies must account for regional differences in regulatory, reimbursement, and healthcare delivery models, requiring bespoke commercial planning.
  • Collaborations between pharmaceutical, biotech, and diagnostic technology providers strengthen innovation pipelines and reinforce market differentiation.

Tariff Impact on Market Dynamics

The 2025 introduction of new US tariff regulations has intensified cost pressures on manufacturers by increasing duties on essential antithrombotic ingredients and finished products. Leaders are responding by diversifying supply chains, increasing local production capacity in tariff-exempt regions, and leveraging strategic partnerships with contract organizations to safeguard operational agility and preserve market competitiveness.

Methodology & Data Sources

This research combines quantitative market analysis with qualitative input from clinical, industry, and procurement stakeholders. Data were drawn from peer-reviewed publications, regulatory sources, proprietary healthcare databases, and specialist interviews across primary regions and market participants. Rigorous triangulation and scenario analysis ensure reliable, validated insights that reflect both empirical trends and real-world decision environments.

Why This Report Matters

  • Equips executive teams with a clear, actionable roadmap for navigating sector disruption and capturing growth in the antithrombotic drugs market.
  • Highlights the practical implications of regulatory changes, digital transformation, and evolving treatment practices for informed portfolio and investment decisions.
  • Enables targeted go-to-market strategies by detailing segment-specific trends, competitive moves, and emerging market opportunities.

Conclusion

Senior stakeholders can rely on this report for decisive, data-driven guidance as the antithrombotic market evolves. Strategic planning that incorporates advancements in therapy, supply chain management, and regional execution will underpin sustainable growth and broader patient impact.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antithrombotic Drugs Market, by Drug Class
8.1. Introduction
8.2. Anticoagulants
8.2.1. Direct Oral Anticoagulants
8.2.1.1. Direct Thrombin Inhibitors
8.2.1.1.1. Dabigatran
8.2.1.2. Factor Xa Inhibitors
8.2.1.2.1. Apixaban
8.2.1.2.2. Edoxaban
8.2.1.2.3. Rivaroxaban
8.2.2. Heparins
8.2.2.1. Low Molecular Weight Heparin
8.2.2.2. Unfractionated Heparin
8.2.3. Vitamin K Antagonists
8.3. Antiplatelets
8.4. Thrombolytics
9. Antithrombotic Drugs Market, by Indication
9.1. Introduction
9.2. Atrial Fibrillation
9.3. Deep Vein Thrombosis
9.4. Myocardial Infarction
9.5. Pulmonary Embolism
9.6. Stroke Prevention
10. Antithrombotic Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Oral
10.2.1. Tablet
10.3. Parenteral
10.3.1. Injection
11. Antithrombotic Drugs Market, by End User
11.1. Introduction
11.2. Home Care
11.3. Hospital
11.4. Retail Pharmacy
12. Americas Antithrombotic Drugs Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Antithrombotic Drugs Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Antithrombotic Drugs Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Bayer Aktiengesellschaft
15.3.2. Pfizer Inc.
15.3.3. Bristol-Myers Squibb Company
15.3.4. Sanofi S.A.
15.3.5. AstraZeneca PLC
15.3.6. Johnson & Johnson
15.3.7. Boehringer Ingelheim International GmbH
15.3.8. Daiichi Sankyo Company, Limited
15.3.9. Novartis AG
15.3.10. Merck & Co., Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ANTITHROMBOTIC DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ANTITHROMBOTIC DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ANTITHROMBOTIC DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ANTITHROMBOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ANTITHROMBOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTITHROMBOTIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 67. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 69. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 70. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 71. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 72. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 73. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 76. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 77. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 87. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 88. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 135. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 136. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 137. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 138. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 139. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 140. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 143. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 144. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 146. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 147. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 148. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 149. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 151. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 152. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 154. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 155. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 169. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 170. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 171. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 172. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 173. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 176. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 177. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 180. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 181. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 182. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 183. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 184. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 187. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 188. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 212. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 224. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 225. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 227. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 228. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 229. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 231. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 232. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 245. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 246. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 247. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 248. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 249. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 250. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 251. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 253. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 254. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 256. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 257. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 258. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 259. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 260. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 261. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 262. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 264. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 265. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 267. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 268. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 270. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 271. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 272. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 276. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 278. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 279. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 289. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 290. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 291. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 292. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 293. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 294. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 295. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 297. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 298. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 300. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 301. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 302. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 303. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 304. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 305. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 306. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 308. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 309. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 310. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 311. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 312. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 316. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 319. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 320. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 321. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 322. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 323. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 324. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 325. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 326. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 327. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 328. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 329. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 330. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 331. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 332. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 333. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 334. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Antithrombotic Drugs market report include:
  • Bayer Aktiengesellschaft
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Sanofi S.A.
  • AstraZeneca PLC
  • Johnson & Johnson
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo Company, Limited
  • Novartis AG
  • Merck & Co., Inc.

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 45.15 Billion
Forecasted Market Value ( USD ) by 2030 $ 60.49 Billion
Compound Annual Growth Rate6.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antithrombotic Drugs - Global Strategic Business Report - Product Image

Antithrombotic Drugs - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
Antithrombotic Drugs Market 2024-2028 - Product Image

Antithrombotic Drugs Market 2024-2028

  • Report
  • 161 Pages
  • Global
From
Factor XI Inhibitors - Pipeline Insight, 2025 - Product Image

Factor XI Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Intracranial Hemorrhage - Pipeline Insight, 2025 - Product Image

Intracranial Hemorrhage - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease - Product Image

Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease

  • Book

About the Antithrombotics Market

Antithrombotics are drugs used to prevent the formation of blood clots, which can lead to cardiovascular diseases such as stroke and heart attack. These drugs work by inhibiting the activity of clotting factors in the blood, thus preventing the formation of clots. Common antithrombotics include aspirin, clopidogrel, warfarin, and heparin. Aspirin is the most widely used antithrombotic, and is often prescribed to reduce the risk of stroke and heart attack. Clopidogrel is used to prevent blood clots in patients with coronary artery disease, while warfarin is used to prevent and treat blood clots in patients with atrial fibrillation. Heparin is used to prevent and treat deep vein thrombosis and pulmonary embolism. The antithrombotics market is highly competitive, with many large pharmaceutical companies offering a range of products. Some of the major players in the market include Bayer, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. These companies are continuously developing new products to meet the needs of patients and healthcare providers. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.